IWK Health Centre
Halifax, Nova Scotia, Canada
NCT Number: NCT04920643
Malformations of the heart are common; 1.35 million infants are born each year with congenital heart disease. Many of these defects carry a considerable threat to the individual's quality of life as well as survival. Along with focused medical management, surgical repair remains a standard of care for more than 25,000 infants and children each year in the United States and Canada. The care of individuals with congenital heart disease is highly complex and has significant risks of morbidity and mortality. Most cardiac operations require the use of cardiopulmonary bypass (CPB, also known as the heart-lung machine) to safely access the inner chambers of the heart. CPB itself has been well documented to cause significant inflammation and hemodilution as the individual's blood is passed through a foreign circuit. This inflammatory response can lead to fluid overload, distributive shock and potential end-organ dysfunction in the heart, lungs, kidneys, brain, liver or bowels. These organ dysfunctions may culminate in post-operative low cardiac output syndrome (LCOS), prolonged ventilation time, prolonged intensive care unit (ICU) stay and can contribute to mortality.
Dampening the inflammatory response from CPB has been a focus of research interest for years. Intra-operative ultrafiltration has been used to remove excess fluids and filter off inflammatory cytokines during cardiac operations. Over 90% of children's heart centers in the world utilize some form of ultrafiltration (mostly some form of modified ultrafiltration), but there are wide variations in published ultrafiltration protocols (none of which are combination SBUF-SMUF in children). Ultimately, this project seeks to provide high-quality evidence that the immunologic and clinical effects of combination SBUF-SMUF are rate dependent. Therefore, a randomized study directly comparing a high-exchange SBUF-SMUF (60ml/kg/hr) and a low-exchange SBUF-SMUF (6ml/kg/hr) can identify which is the optimal ultrafiltration protocol to enhance post-operative clinical outcomes for this patient population. The expected data and results could be immediately applicable to improve recovery after heart surgery for infants and children across Canada and the rest of the world at large.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Halifax, Nova Scotia, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ultrafiltration is used during cardiac surgery with cardiopulmonary bypass to remove both fluid and small molecules such as inflammatory cytokines from the patient's circulation.
Time frame: Up to 5 days
Time frame: Up to 5 days
Taken in time series at ICU admission, 0, 12, 24, 36, 48, 72, 96 and 120 hours.
Time frame: Up to 5 days
Taken in time series at ICU admission, 0, 12, 24, 36, 48, 72, 96 and 120 hours.
Time frame: Up to 5 days
Taken in time series at ICU admission, 0, 12, 24, 36, 48, 72, 96 and 120 hours.
Time frame: Up to 28 days
Time frame: Up to 28 days
Time frame: Up to 3 days
Defined by any one of the following within the first 72 post-operative hours:
Time frame: Up to 3 days
Defined by any one of the following with the first 72 post-operative hours:
Time frame: Up to 2 days
Vasoactive-inotrope score at 48 hours equal to or greater than that at ICU admission.
Time frame: Up to 28 days
Time frame: Measured at 1 day
Time frame: Up to 30 days
Time frame: Up to 1 day
C3, C3a, C3b, C5, C5a, IL-1, IL1-Ra, IL-6, IL-10, TNF, CXCL-8 among others. The final selection of mediators will be subject to final pilot study results and assay availability. Taken at baseline, 0 hours and 24 hours after CPB.
Time frame: Up to 7 days
Total loop diuretic (mg/kg), measured in furosemide equivalents, during the first 7 post-operative days.
Time frame: Up to 5 days
Time frame: Up to 5 days
Time frame: Up to 5 days
Time frame: Up to 28 days
Mechanical ventilation for more than 7 days
Time frame: Up to 28 days
Time frame: Up to 28 days
KDIGO Criteria
Time frame: Up to 30 days
Time frame: Up to 60 days
Time frame: Up to 1 day
Time frame: Up to 5 days
Time frame: Up to 5 days
Measured by arterial blood gas (mM)
Time frame: Up to 5 days
Blood Concentration (uM)
Time frame: Up to 5 days
Taken in time series at ICU admission, 12, 24, 36, 48, 72, 96 and 120 hours.
IWK Health Centre
Other
High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery (ULTRA): A Canadian Randomized Controlled Trial
Acronym: ULTRA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01952171
Cardiovascular Abnormalities, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05902013
Airway Complication of Anesthesia, Cardiovascular Abnormalities
Vienna, State of Vienna, Austria
View Trial DetailsNCT06650787
Cardiovascular Abnormalities, Cardiovascular Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05524324
Cardiovascular Abnormalities, Cardiovascular Diseases
Caen, France
View Trial Details